Finanzwire Finanzwire
Basculer en Français
9774 Companies
195610 Keywords
126593 Articles
103988 Press releases
Headlines Articles Press releases MAAT PHARMA Remove
  1. Home
  2. Companies
  3. MAAT PHARMA
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • PRESS RELEASE

    published on 05/15/2024 at 07:30, 1 year 8 months ago

    Inside Information / News release on accounts, results

    MaaT Pharma announces successful completion of 19.2 million euros Global Offering with new shares, aims to fund R&D activities, Phase 3 trials, and broaden pipeline
    Biotechnology Fundraising Clinical Trials Global Offering MaaT Pharma
    Logo of MAAT PHARMA
  • BRIEF

    published on 05/14/2024 at 19:39, 1 year 8 months ago

    MaaT Pharma Announces 18 Million Euro Global Offering and Strategic Developments

    Financial Strategy Phase 3 Trial Clinical-stage Biotechnology Global Offering Microbiome Ecosystem Therapies
  • PRESS RELEASE

    published on 05/14/2024 at 19:34, 1 year 8 months ago

    Inside Information / News release on accounts, results

    MaaT Pharma launches a global offering of approximately 18 million euros to fund R&D activities and expand shareholder base. Current shareholders commit to significant subscriptions
    Global Offering MaaT Pharma 18 Million Euros R&D Activities Shareholder Commitments
    Logo of MAAT PHARMA
Previous page
1 ... 4 5
Accesswire
  • Published on 01/30/2026 at 08:35, 1 hour 12 minutes ago

    Alaska Energy Metals Announces Closing Of Life Offering of Units

  • Published on 01/30/2026 at 08:00, 1 hour 47 minutes ago

    Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property

  • Published on 01/30/2026 at 02:15, 7 hours 32 minutes ago

    Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension

  • Published on 01/30/2026 at 00:00, 9 hours 47 minutes ago

    LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

  • Published on 01/29/2026 at 23:00, 10 hours 47 minutes ago

    PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A

View all ACCESSWIRE
EQS Group
  • Published on 01/30/2026 at 09:00, 46 minutes ago

    Original-Research: 123fahrschule SE (von NuWays AG): BUY

  • Published on 01/30/2026 at 09:00, 46 minutes ago

    Original-Research: q.beyond AG (von NuWays AG): BUY

  • Published on 01/30/2026 at 09:00, 47 minutes ago

    Official List Notice

  • Published on 01/30/2026 at 08:29, 1 hour 18 minutes ago

    Notice of Early Redemption

  • Published on 01/30/2026 at 08:00, 1 hour 47 minutes ago

    Ørsted to present its annual report for 2025 on February 6

View all EQS
Les Echos
  • Published on 01/30/2026 at 08:00, 1 hour 47 minutes ago

    AMA: 4th Quarter & FY 2025 Revenues

  • Published on 01/29/2026 at 18:00, 15 hours 47 minutes ago

    GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%

  • Published on 01/29/2026 at 17:45, 16 hours 2 minutes ago

    LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE

  • Published on 01/29/2026 at 17:45, 16 hours 2 minutes ago

    Cegedim generated LFL revenue growth of 1.1% in 2025

  • Published on 01/29/2026 at 17:40, 16 hours 7 minutes ago

    ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy